AU2020903727A0 - Conjugates and their use in therapy - Google Patents

Conjugates and their use in therapy

Info

Publication number
AU2020903727A0
AU2020903727A0 AU2020903727A AU2020903727A AU2020903727A0 AU 2020903727 A0 AU2020903727 A0 AU 2020903727A0 AU 2020903727 A AU2020903727 A AU 2020903727A AU 2020903727 A AU2020903727 A AU 2020903727A AU 2020903727 A0 AU2020903727 A0 AU 2020903727A0
Authority
AU
Australia
Prior art keywords
conjugates
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020903727A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centenary Institute of Cancer Medicine and Cell Biology
University of Sydney
Original Assignee
Centenary Institute of Cancer Medicine and Cell Biology
University of Sydney
Filing date
Publication date
Application filed by Centenary Institute of Cancer Medicine and Cell Biology, University of Sydney filed Critical Centenary Institute of Cancer Medicine and Cell Biology
Publication of AU2020903727A0 publication Critical patent/AU2020903727A0/en
Priority to EP21878793.5A priority Critical patent/EP4228710A1/en
Priority to JP2023547721A priority patent/JP2023547954A/en
Priority to AU2021359638A priority patent/AU2021359638A1/en
Priority to CA3195410A priority patent/CA3195410A1/en
Priority to MX2023004327A priority patent/MX2023004327A/en
Priority to PCT/AU2021/051203 priority patent/WO2022077068A1/en
Priority to CN202180075143.7A priority patent/CN116472068A/en
Priority to IL302033A priority patent/IL302033A/en
Priority to KR1020237015744A priority patent/KR20230130610A/en
Priority to US18/299,304 priority patent/US20230398240A1/en
Pending legal-status Critical Current

Links

AU2020903727A 2020-10-14 2020-10-14 Conjugates and their use in therapy Pending AU2020903727A0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
KR1020237015744A KR20230130610A (en) 2020-10-14 2021-10-14 Therapeutic radiolabeled conjugates and their use in therapy
MX2023004327A MX2023004327A (en) 2020-10-14 2021-10-14 Therapeutic radiolabelled conjugates and their use in therapy.
JP2023547721A JP2023547954A (en) 2020-10-14 2021-10-14 Therapeutic radiolabeled conjugates and their use in therapy
AU2021359638A AU2021359638A1 (en) 2020-10-14 2021-10-14 Therapeutic radiolabelled conjugates and their use in therapy
CA3195410A CA3195410A1 (en) 2020-10-14 2021-10-14 Therapeutic radiolabelled conjugates and their use in therapy
EP21878793.5A EP4228710A1 (en) 2020-10-14 2021-10-14 Therapeutic radiolabelled conjugates and their use in therapy
PCT/AU2021/051203 WO2022077068A1 (en) 2020-10-14 2021-10-14 Therapeutic radiolabelled conjugates and their use in therapy
CN202180075143.7A CN116472068A (en) 2020-10-14 2021-10-14 Therapeutic radiolabeled conjugates and their use in therapy
IL302033A IL302033A (en) 2020-10-14 2021-10-14 Therapeutic radiolabelled conjugates and their use in therapy
US18/299,304 US20230398240A1 (en) 2020-10-14 2023-04-12 Therapeutic radiolabelled conjugates and their use in therapy

Publications (1)

Publication Number Publication Date
AU2020903727A0 true AU2020903727A0 (en) 2020-11-05

Family

ID=

Similar Documents

Publication Publication Date Title
EP3981434A4 (en) Anti-b7-h4 antibody-drug conjugate and medicinal use thereof
EP3668972A4 (en) Engineered dnase enzymes and use in therapy
IL182652A0 (en) Nitrobenzindoles and their use in cancer therapy
EP4074345A4 (en) Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
EP3936150A4 (en) Antibody-drug conjugates including antibody against human dlk1, and use thereof
EP3762032A4 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
AU316679S (en) Therapeutic device
AU2022299173A1 (en) Novel therapeutic delivery moieties and uses thereof
EP3630099A4 (en) Bax activators and uses thereof in cancer therapy
EP3836950A4 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
IL274122A (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
EP3937980A4 (en) Modified micrornas and their use in the treatment of cancer
EP4157290A4 (en) Compositions, their uses in therapy and methods thereof
AU2020903727A0 (en) Conjugates and their use in therapy
EP3753579A4 (en) Anti-trailr2 antibody-toxin-conjugate and pharmaceutical use thereof in anti-tumor therapy
EP3995498A4 (en) Thienopyrimidine derivatives having stereo configurations and use thereof in medicine
AU2022900994A0 (en) Conjugates and their use in therapy
GB202014736D0 (en) Novel compounds and their use in therapy
IL309249A (en) Conjugates comprising phosphoantigens and their use in therapy
IL299254A (en) Tubulysins and protein-tubulysin conjugates
EP3960242A4 (en) Conjugate and cancer therapeutic agent
AU2020901760A0 (en) Nanoparticle conjugates and their use in therapeutic applications
EP3999092A4 (en) Combination cancer therapy agents and methods
EP3959242A4 (en) Anthracycline antibody-drug conjugates and uses thereof
EP3833352A4 (en) Non-polyamine based polyamine transport inhibitors and their use in the treatment of human cancers